louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06877039: Characteristics of Clinical Laboratory Indicators in Patients with Dengue Fever
Official title: Observational Study on the Characteristics of Clinical Laboratory Indicators in Patients with Dengue Fever
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Dengue Fever
Lead sponsor: Foshan Hospital of Traditional Chinese Medicine
Sponsor class: OTHER
First posted: 2025-03-14
Enrollment: 500
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The subjects in this study were dengue fever patients.

Brief summary: The objective of this observational study was to understand the changes in laboratory indicators and clinical manifestations of dengue patients at various ages, and to provide new ideas for the treatment and prevention of dengue. The main questions it aims to answer are: 1 What are the key abnormal items in blood routine indicators of dengue patients? 2 Does dengue affect liver function in patients? Will there be liver damage? And when? 3. What are the specific clinical manifestations of dengue patients?


Eligibility criteria: * Inclusion Criteria\*\*:

  * Meet the clinical diagnostic criteria for dengue fever, with blood indicators showing that the dengue antigen is positive.
  * No age limit for inclusion.
  * Voluntarily agree to participate in the study and sign the informed consent.
  * Complete clinical data available, including symptoms and laboratory tests, to support subsequent analysis.
* Exclusion Criteria\*\*:

  * Incomplete or unavailable clinical data. Patients will be excluded if sufficient laboratory data and symptoms cannot be collected.
  * Unable to understand or unwilling to sign the informed consent for any reason.

Primary outcomes:
measure: WBC
timeFrame: From January 2024 to December 2024
measure: HGB (Hemoglobin)
timeFrame: From January 2024 to December 2024
measure: PLT (Platelet count)
timeFrame: From January 2024 to December 2024
measure: ANC (Absolute Neutrophil Count)
timeFrame: From January 2024 to December 2024
Secondary outcomes:
Other outcomes:
Locations:
city: Foshan
country: China
facility: Foshan Hospital of Traditional Chinese Medicine, Guangzhou University of Chinese Medicine, Foshan, 528051, Guangdong, China.
state: Guangdong
Study officials:
References:
Clinical trial NCT04291339: Comparison of the Efficacy of High-flow Nasal Oxygen Therapy and Facial Mask Ventilation on the Increase of the Oxygen Reserve Index During Anesthetic Induction
Official title: Comparison of the Efficacy of High-flow Nasal Oxygen Therapy and Facial Mask Ventilation on the Increase of the Oxygen Reserve Index During Anesthetic Induction
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Adult Patients 20 Years of Age or Older Who Are Planning to Undergo Surgery Under General Anesthesia
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2020-03-02
Enrollment: 198
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to compare the ability of oxygenation with high-flow nasal oxygen therapy and mask ventilation technique for induction of anesthesia in adult patients who are planning to undergo surgery under general anesthesia.


Eligibility criteria: Inclusion Criteria:

* adult patients aged over 19 years who are scheduled for sleep endoscopy

Exclusion Criteria:

* basal skull fracture
* facial anomaly
* consciousness disorder
* Risk of aspiration
* necessity of awake fiberoptic intubation due to the large vocal cord mass, endotracheal tumor or bleeding.

Primary outcomes:
measure: Peak oxygen reserve index value
timeFrame: for 10 minutes during anesthetic induction. At Day 0.
Secondary outcomes:
measure: The time to achieve the peak oxygen reserve index value
timeFrame: for 10 minutes during anesthetic induction. At Day 0.
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Severance Hospital, Yonsei University Health System
Study officials:
References:
Clinical trial NCT00890539: Methacholine Challenge: Comparison of Doubling and Quadrupling Methacholine Dose Regimes Using the Tidal Volume Method
Official title: Methacholine Challenge: Comparison of Doubling and Quadrupling Methacholine Dose Regimes Using the Tidal Volume Method
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Asthma
Lead sponsor: University of Saskatchewan
Sponsor class: OTHER
First posted: 2009-04-30
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this study is to determine the difference (if any) in the result of the methacholine challenge (a test used by physicians in diagnosing asthma) when concentrations of methacholine are quadrupled versus doubled.

Detailed description: The purpose of this study is to confirm that the tidal volume technique of methacholine delivery may be employed in methacholine challenges using a quadrupling dose schedule instead of the standard doubling dose schedule with similar diagnostic efficacy, with no increase in patient adverse events, and with a shorter investigational duration. This has previously been shown to be true using the dosimeter technique of methacholine challenge.

Eligibility criteria: Inclusion Criteria:

* You must be over 18 years of age; and
* You must have a diagnosis of asthma; and
* Excluding asthma, you are not aware of any other lung conditions or diseases.

Exclusion Criteria:

* You have a known hypersensitivity (i.e. an overreaction of your immune system) to methacholine or other parasympathomimetic agents or cholinesterase inhibitors (i.e. agents that act in a similar way via your nervous system - to be discussed with study personnel); or
* You are a nursing mother or if you are a woman of child bearing potential who is, may be, or intends to become pregnant during testing as the effects of methacholine inhalation in these situations are not known; or
* Your baseline lung function is poor (ie. your FEV or forced expiratory volume in one second, is less than 65% of your predicted values). This will be performed and explained by study personnel prior to commencing methacholine inhalation testing; or
* You have had any respiratory infections for the last four weeks; or
* If you have allergies, and have been exposed to agents that trigger your asthma within the last four weeks; or
* If you have any significant chronic medical condition.

Primary outcomes:
measure: Methacholine PC20
timeFrame: 1 week
Secondary outcomes:
measure: Subject measure of breathlessness - modified Borg scale
timeFrame: 1 week
Other outcomes:
Locations:
city: Saskatoon
country: Canada
facility: University of Saskatchewan
state: Saskatchewan
Study officials:
affiliation: University of Saskatchewan
name: Donald W Cockcroft, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04136639: The Anticariogenic Effect of Miswak (Silvadora Persica) and Grape Seed Extract
Official title: The Anticariogenic Effect of Miswak (Silvadora Persica) and Grape Seed Extract
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dental Caries
Lead sponsor: Al-Azhar University
Sponsor class: OTHER
First posted: 2019-10-23
Enrollment: 30
Sex: ALL
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Prevention of dental caries has taken a great importance in the last decade. The use of herbal and natural products became mandatory to avoid the side effects of commercially available medications. Aim of the study; the aim was to investigate the anti-cariogenic effect of miswak and grape seed extract (GSE).

Detailed description: Patients used Miswak sticks, grape seed extract mouth wash and fluoride mouthwash twice daily for three month. Saliva samples were collected at base line and after one month and three month. Assessment of bacterial count and saliva buffering capacity were performed at base line and after one and three month.

Eligibility criteria: Inclusion Criteria:

* Patients with high caries risk
* Males or females
* Medically free patients
* Patients approving to participate in the study

Exclusion Criteria:

* Patients who were on antibiotic therapy or corticosteroid therapy for 30 days before the examination
* Patients had history of professional cleaning in the last 15 days
* Patients with exposed pulp
* Evidence of parafunctional habits
* Patients with developmental dental anomalies
* Patients undergoing or will start orthodontic treatment
* Patients with removable prosthesis
* Periapical Abscess or Fistula

Primary outcomes:
measure: quantitative measure of the change in salivary streptococcus mutans Count from baseline to one month and three months.
timeFrame: Baseline, one month, three months.
Secondary outcomes:
measure: quantitative measure of the change in saliva buffering capacity from baseline to one month and three months.
timeFrame: baseline, one month , three months
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Al Azhar University
state: Nasr City
Study officials:
affiliation: Al-Azhar University
name: Maha Niazy, Professor
role: STUDY_DIRECTOR
References:
Clinical trial NCT04695639: Selective Motor Control and Upper Extremity Functions in Children With Hemiparetic Cerebral Palsy
Official title: Correlation Between Selective Motor Control and Upper Extremity Functions in Children With Hemiparetic Cerebral Palsy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cerebral Palsy
Keywords: Cerebral pals
selective voluntary motor control
upper extremity function
hand grip strength
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2021-01-05
Enrollment: 46
Sex: ALL
Minimum age (years): 4
Maximum age (years): 8
Standard ages: CHILD
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Participants will be recruited from the Outpatient Clinic of Faculty of Physical Therapy, Cairo University, Abo El-reesh Hospital and the Outpatient Clinic of Al-Minya General Hospital, Al-Minya Governorate.

Brief summary: Identification of musculoskeletal and neuromuscular factors that affect the integrity and functional performance in children with cerebral palsy is very essential as it enables multidisciplinary rehabilitation team to design the proper intervention to improve functional performance and independence for those children.

Detailed description: Limited literature is available regarding the relation between selective voluntary motor control and motor functions in children with cerebral palsy. Up to our knowledge this is the first study intending to investigate the influence of selective voluntary motor control on upper extremity function in children with spastic cerebral palsy. Therefore, the current study will be conducted to investigate the correlation between selective voluntary motor control and upper extremity functions in children with spastic hemiparetic cerebral palsy.

It is hypothesized that:-

1. There is no relation between SVMC and upper limb function in children with spastic hemiparetic CP.
2. There is no relation between upper extremity SVMC and hand grip strength in children with spastic hemiparetic CP.

Eligibility criteria: Inclusion Criteria:

* Age ranges from 4 to 8 years.
* Both genders.
* Diagnosis of spastic hemiparetic cerebral palsy.
* Level I-IV on Manual Ability Classification System.
* Spasticity grade 1 to 2 on Modified Ashworth Scale.
* Level I-III on Gross Motor Classification System .

Exclusion Criteria:

* Significant mental or psychological problems.
* Significant visual/auditory problem.
* Botox injection and/or surgery of the upper limb in the past 12 months.
* Fixed deformities in the affected upper extremity.

Primary outcomes:
measure: Test of Arm Selective Control
timeFrame: 1/2/2021 to 30/4/2021
Secondary outcomes:
measure: Hand Held Dynamometer
timeFrame: 1/2/2021 to 30/4/2021
measure: Quality of Upper Extremity Skill Test
timeFrame: 1/2/2021 to 30/4/2021
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: faculty of physical therapy, Cairo university
Study officials:
affiliation: Cairo University
name: Maya Galal, Phd
role: STUDY_DIRECTOR
affiliation: Cairo University
name: Radwa Gomaa
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01630239: MR-Guided Laser Ablation of Hepatic Tumors
Official title: Technical Success, Safety, and Short-term Efficacy for MR-Guided Laser Ablation of Hepatic Tumors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Soft Tissue Tumors
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2012-06-28
Enrollment: 1
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a pilot study to investigate the performance of MR-guided Laser Induced Thermal Therapy (LITT) in the treatment of liver tumors.


Eligibility criteria: Inclusion Criteria:

* Patients with soft tissue tumor metastases to the liver who are referred to Interventional Radiology for treatment.
* Surgery is not a viable or desirable alternative therapy at the time of enrollment
* Radiation therapy has failed or not indicated or can be safely postponed
* Tumor size ≤ 5 cm at its largest diameter
* Tumor position is not in the central liver hilum
* Performance status is ECOG 2 or better in adults
* Patient is able to undergo MRI

Exclusion Criteria:

* Patients with pacemaker or defibrillator
* Patients with metallic surgical clips close to the site of the intended ablation
* Pregnant women
* Patients with hilar liver lesions

Primary outcomes:
measure: MR Images
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: David Woodrum, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05899439: Immune Function and the Progression to T1D
Official title: Immune Function and the Progression to Type 1 Diabetes:
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Type 1 Diabetes
Lead sponsor: University of Florida
Sponsor class: OTHER
Collaborators: name: Juvenile Diabetes Research Foundation
name: National Institute of Allergy and Infectious Diseases (NIAID)
First posted: 2023-06-12
Enrollment: 2800
Sex: ALL
Minimum age (years): 0
Maximum age (years): 100
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Individuals age 0 to 100 with or without a diagnosis of type 1 diabetes and able/willing to have a blood draw

Brief summary: To elucidate the mechanisms by which type 1 diabetes-associated genes; IFIH1, TYK2, IKZF4, as well as total genetic risk, impart functional immunoregulatory abnormalities that result in expansion of self-reactive adaptive immune cells, defective regulatory/effector mechanisms in T cells, inflammatory antigen presenting cells, and abnormal immune function in T cells and B cells.

Detailed description: Newly proposed studies will identify the inflammatory cues that draw immune cells into islets for disease initiation (Project 1); probe the motility of immune cells through inflamed vasculature to the target organ and antigen priming sites within secondary lymphatics (Project 2); and characterize the T1D-associated adaptive immune signatures in blood and immune tissues (Project 3).

The overall hypothesis of the renewed P01 states: 1) the impact of T1D-risk variants will vary by tissue, cell subset, and activation state, and 2) risk variants, cellular stress, and defects in immunologic pathways are key to engender the autoimmune destruction of pancreatic B-cells that results in T1D.

Eligibility criteria: Inclusion Criteria: able to have blood drawn -

Exclusion Criteria: none

-

Primary outcomes:
measure: the number of participants who become at risk for development of type 1 diabetes
timeFrame: through study completion, up to 25 years
measure: Genetic risk of type 1 diabetes
timeFrame: through study completion, up to 25 years
Secondary outcomes:
Other outcomes:
Locations:
city: Gainesville
country: United States
facility: Kieran McGrail
state: Florida
city: Columbus
country: United States
facility: The Ohio State University
state: Ohio
city: Houston
country: United States
facility: Baylor College of Medicine, Center for Research Advancement - Texas Children's Hospital
state: Texas
Study officials:
References:
Clinical trial NCT04387539: ٍٍSofosbuvir/Simeprevir/Daclatasvir/Ribavirin and HCV Genotype 4-infected Egyptian Experienced Participants
Official title: A Sofosbuvir-based Quadruple Regimen is Highly Effective in HCV Type 4-infected Egyptian Patients With DAA Treatment Failure
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Chronic Hepatitis C Virus Infection
Keywords: Chronic HCV GT4
Sofosbuvir
Simeprevir
Daclatasvir
Ribavirin
Experienced
Lead sponsor: Beni-Suef University
Sponsor class: OTHER
First posted: 2020-05-14
Enrollment: 94
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Experienced participants who had HCV GT4 infection were treated with Sofosbuvir/Simeprevir/Daclatasvir/Ribavirin (SOF/SMV/DCV/RBV)

Detailed description: Experienced participants, who had chronic infection with HCV GT4 , and failed prior DAA treatments, SOF/DCV (71/92) or SOF/SMV (15/92) or SOF/pegylated interferon/RBV (2/92) or SOF/RBV (4/92) were enrolled in the current study.

In the present study, the regimen used was designed by the combination of triple DAAs with different mechanisms of action and non-overlapping resistance profiles, SOF/SMV/DCV, plus RBV.

Eligibility criteria: Inclusion Criteria:

* Experienced Egyptian participants with HCV GT4 infection who had failed prior DAA treatments \[SOF/DCV or SOF/SMV or SOF/pegylated interferon/RBV or SOF/RBV\]
* Fibrosis-4 score in non-cirrhotic participants is \<1.45-3.25: (None or moderate fibrosis)
* Fibrosis-4 score in cirrhotic participants is \>3.25: (Advanced fibrosis or cirrhosis)

Exclusion Criteria:

* HCV coinfected with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)
* had any liver disease other than chronic HCV GT4 infection.
* had a history of liver decompensation
* serum a-fetoprotein (AFP) \> 100 ng/ml
* evidence of hepatocellular carcinoma
* major severe illness such as respiratory, renal, heart failure or autoimmune disease
* non-compliance with treatment.

Primary outcomes:
measure: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) in Each Treatment Arm
timeFrame: 12 weeks after last dose
measure: Number of Participants With Adverse Events in Each Treatment Arm
timeFrame: Screening up to 12 weeks after last dose
Secondary outcomes:
measure: Percentage of Participants With Viral relapse
timeFrame: Up to 12 weeks after last dose
Other outcomes:
Locations:
city: Bani Sweif
country: Egypt
facility: Health Administration at Beni-Seuf
Study officials:
affiliation: Biochemistry Dep., Faculty of Science, Beni-Suef University, P.O. Box 52621
name: Mohammed Abdel-Gabbar, Ass. Prof
role: PRINCIPAL_INVESTIGATOR
References:
citation: Abdel-Moneim A, Aboud A, Abdel-Gabbar M, Zanaty MI, Ramadan M. A sofosbuvir-based quadruple regimen is highly effective in HCV type 4-infected Egyptian patients with DAA treatment failure. J Hepatol. 2018 Jun;68(6):1313-1315. doi: 10.1016/j.jhep.2018.03.010. Epub 2018 Apr 3. No abstract available.
Clinical trial NCT04655339: Laparoscopic Transversus Abdominis Plane (TAP) Block to Reduce Post-operative Opioids
Official title: Efficacy of Laparoscopic Transversus Abdominis Plane (TAP) Block to Reduce Post-operative Opioids Following Bariatric and Minimally Invasive Foregut Surgery
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
PHASE3
Conditions: Opioid Use
Lead sponsor: Baylor Research Institute
Sponsor class: OTHER
First posted: 2020-12-07
Enrollment: 165
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In this study we aim to investigate the efficacy of laparoscopic-guided TAP block in reducing post-operative opioid use following minimally invasive foregut and bariatric surgeries. We will also compare and report the analgesia produced by Bupivacaine HCL vs Exparel ®, a prolonged slow release Liposomal Bupivacaine formulation. Secondary outcomes assessed will be VAS pain scores, length of stay, and PONV dosage administered.


Eligibility criteria: Inclusion Criteria:

* gastric bypass \& sleeve gastrectomy, duodenal switch and minimally invasive elective anti-reflux foregut surgeries such as - hiatal hernia repair, fundoplication and Heller myotomy.

Exclusion Criteria:

* Subjects who are known to be i. Allergic to Bupivacaine ii. Chronic opioid users Page 4 iii. Had/have neurological conditions iv. Have a diagnosis of chronic pain syndrome which requires them to consume regular analgesics \> 3-months v. American Society of Anesthesiologists (ASA) Class IV \& V patients with severe systemic disease that is a constant threat to life.

vi. Patients with abdominal drain use vii. Patients with significant cardiovascular, liver or renal disease viii. Presence of contraindications for bariatric or foregut surgery. ix. Patients presenting postoperative complications will be excluded from final analysis \& final data set x. History of bariatric or foregut surgery xi. Patients who are pregnant xii. Patients who are under the age of 18

Primary outcomes:
measure: opioid dosage requested
timeFrame: 30days
Secondary outcomes:
measure: visual analog scores (VAS)
timeFrame: 30days
measure: length of stay
timeFrame: 30days
measure: anti-emetic dosage
timeFrame: 30days
Other outcomes:
Locations:
Study officials:
References: